The groups spend big on Terns and Arcellx.
ApexOnco Front Page
Recent articles
J&J’s Tecvayli/Darzalex nod was the second under a new priority voucher scheme.
JP Morgan approaches.
The company hands its PD-L1 x VEGF bispecific back to ImmuneOnco.
Seven oncology approvals included nods for subcutaneous Rybrevant and Lunsumio.
Mocertatug rezetecan is starting its first western pivotal trials.
PersonGen’s LV009 takes the industry tally of clinical-stage projects to 14.
The holiday period included Genmab’s discontinuation of acasunlimab.
